1. Scrip
  2. >>R&D

Deciphering Molnupiravir’s India Trial Discontinuation In Moderate COVID-19

 
• By Anju Ghangurde

Two Indian firms want to terminate specific Phase III trials for molnupiravir, the Merck/ Ridgeback Biotherapeutics’ antiviral in the spotlight as a treatment for mild-to-moderate COVID-19. Should much be read into these plans or is it merely an “administrative closure” that is being sought?

molnupiravir
Spotlight On Molnupiravir Trials • Source: Alamy

Amid buoyant expectations about the prospects of Merck & Co., Inc. and Ridgeback Biotherapeutics LP ‘s molnupiravir in COVID-19 following some standout data, two Indian firms including licensee Aurobindo Pharma Limited have sought to stop Phase III studies for the investigational oral antiviral in patients with moderate disease creating a flutter in the country.

Things were further compounded when a report quoted an unnamed official in the Indian regulatory system as saying that the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.